We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Alimera Sciences, pSivida Limited Amend Medidur™ FA Collaboration Agreement
News

Alimera Sciences, pSivida Limited Amend Medidur™ FA Collaboration Agreement

Alimera Sciences, pSivida Limited Amend Medidur™ FA Collaboration Agreement
News

Alimera Sciences, pSivida Limited Amend Medidur™ FA Collaboration Agreement

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Alimera Sciences, pSivida Limited Amend Medidur™ FA Collaboration Agreement"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Alimera Sciences and pSivida Ltd have announced that they have amended their license and collaboration agreement relating to Medidur™ FA, the companies’ Phase III investigative treatment for diabetic macular edema (DME), and other Medidur products.

Alimera is increasing its equity in the future profits of Medidur FA from 50 to 80 percent in exchange for consideration of up to approximately US$78m to pSivida.

Consideration to pSivida includes an up-front payment of US$12m, a US$25m milestone payment upon FDA approval of Medidur™ FA, other payments of up to approximately US$21m by September 30, 2012, and assumption of pSivida's research and development funding obligations estimated at approximately US$20m.

“We are very pleased with this agreement as it provides us with the opportunity to increase our stake and consolidate the development and commercialization of our late stage DME product Medidur FA,” said Dan Myers, President and CEO of Alimera Sciences.

“In addition, we will further advance the delivery system’s application in other serious ophthalmic conditions like dry age-related macular degeneration (AMD), using exploratory treatments such as the groundbreaking work we are doing around NADPH oxidase inhibitors.”

"We believe this is a great deal for pSivida and its shareholders as it gives the company a significant financial interest in very exciting products and economics that eliminate our need for equity financing for the foreseeable future under our current plans,” said pSivida Managing Director, Dr. Paul Ashton.

“This new agreement with Alimera Sciences is expected to significantly reduce our burn rate going forward as the Company’s two lead ophthalmology programs in development are now funded by our partners."

Advertisement